Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests

12.07.2013
A recently discovered form of the protein that triggers blood clotting plays a critical role in promoting the growth of metastatic pancreatic cancer and primary breast cancer, according to the cumulative findings from two new scientific manuscripts published online ahead of print in the International Journal of Cancer and PNAS (Proceedings of the National Academy of Sciences).

The protein, called "Tissue Factor," is present in various tissues—for example, walls of blood vessels. Earlier studies suggested that alternatively spliced Tissue Factor (asTF) may contribute to cancer growth, but the molecular events leading to this were previously unknown.

New research conducted through an international collaboration between the labs of Vladimir Bogdanov, PhD, of the University of Cincinnati Cancer Institute, and Henri Versteeg, PhD, of the Einthoven Laboratory for Experimental Vascular Medicine at the Leiden University Medical Center in Leiden, the Netherlands, articulates how asTF fuels growth and metastasis of solid cancers.

Using preclinical animal models, Bogdanov and Versteeg's teams obtained the first scientifically validated evidence that asTF promotes the spread of pancreatic cancer and promotes primary growth of breast cancer tumors.

"We have demonstrated that targeting asTF with a novel monoclonal antibody—developed based on our 10 years of studying asTF—also stops the growth of breast cancer in an animal model, giving us a promising new target to fight certain forms of breast cancer," says Bogdanov, who originally described asTF in 2003. UC filed a patent for this technology in January 2013.

Bogdanov and Versteeg presented their findings at the XXIV Congress of the International Society on Thrombosis and Haemostasis in Amsterdam, the Netherlands (held June 29-July 4, 2013).

"Many molecules on the surface of cells—including integrins—are important for the function of both normal and cancerous cells, so targeting integrins for stopping the growth of cancer is not a promising strategy. What is unique about asTF is that it binds to integrins on vessel-forming cells, activating them. We've shown that certain cancer cells share those same qualities, so if you target asTF—which is elevated in cancer—there is significant potential to spare the 'good' parts of the cellular system while removing the 'bad' cancer-specific protein from the game," explains Bogdanov.

"Many routine therapies such as chemotherapy or radiation may not always be efficient. Targeting asTF in tumors using our monoclonal antibody may form a potent additional anticancer strategy in combination with conventional avenues", says Versteeg.

This work was funded by National Institutes of Health/National Cancer Institute grant 1R21CA160293-01A1 and the Netherlands Organization for Scientific Research VIDI grant 91710329. Authors on both manuscripts have no conflicts of interest to report.

Collaborators in the International Journal of Cancer study include UC's Dusten Unruh, Kevin Turner, DO, Ramprasad Srinivasan, PhD, Xiaoyang Qi, PhD, Zhengtao Chu, , David Plas, PhD, Catherine Gallo, Syed Ahmad, MD, and Fred Lucas, MD; Begum Kocaturk, PhD, of Einthoven Laboratory for Experimental Vascular Medicine; Bruce Aronow, PhD, of Cincinnati Children's Hospital Medical Center; Holger Kalthoff, PhD, of the Institute of Experimental Cancer Research (Germany); Daniel Krichhofer, PhD of Genentech (California); and Wolfram Ruf, MD, of the Scripps Research Institute (California).

Collaborators in the PNAS study include Begum Kocaturk, PhD, and Yascha Van den Berg, MD, PhD, Martijn van der Ent, PhD, Pieter Reitsma, PhD and Susanne Osanto, PhD, of Einthoven Laboratory for Experimental Vascular Medicine; Chris Tieken, PhD, J. Sven D. Mieog, PhD, Charla Engels, PhD, Peter Kuppen, PhD, Cornelis Van de Velde, PhD, and Gerrit-Jan Liefers, PhD, of Leiden University Medical Center; and Dr Ruf of the Scripps Research Institute.

Amanda Harper | EurekAlert!
Further information:
http://www.uc.edu

More articles from Health and Medicine:

nachricht Potential seen for tailoring treatment for acute myeloid leukemia
10.12.2018 | University of Washington Health Sciences/UW Medicine

nachricht UC San Diego researchers develop sensors to detect and measure cancer's ability to spread
06.12.2018 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

Im Focus: Substitute for rare earth metal oxides

New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals

Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.

Im Focus: A bit of a stretch... material that thickens as it's pulled

Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.

Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...

Im Focus: The force of the vacuum

Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.

The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

Expert Panel on the Future of HPC in Engineering

03.12.2018 | Event News

 
Latest News

Small but ver­sat­ile; key play­ers in the mar­ine ni­tro­gen cycle can util­ize cy­anate and urea

10.12.2018 | Life Sciences

New method gives microscope a boost in resolution

10.12.2018 | Physics and Astronomy

Carnegie Mellon researchers probe hydrogen bonds using new technique

10.12.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>